Table 3.
Effect of i.p. treatment with interferon alfacon-1, ribavirin, and viramidine in hamsters infected with hamster-adapted yellow fever virus
| Toxicity controls
|
YFV-infected
|
||||||
|---|---|---|---|---|---|---|---|
| Treatment | Dose, schedule | Surv/totala | Weight change (g)b | Surv/total | MDDc | ALT (6 dpi) | Weight change (g)b |
| IFN alfacon-1 | 5 μg/kg/d, -4 h-6 dpi, qd | 3/3 | 7.0 | 10/10*** | >21 ± 0.0 | 60 ± 6.0*** | 5.1 ± 3.3*** |
| IFN alfacon-1 | 1.6 μg/kg/d, -4 h-6 dpi, qd | -- | -- | 9/10** | 8.0 ± 0.0 | 89 ± 60** | 2.7 ± 5.5** |
| IFN alfacon-1 | 0.5 μg/kg/d, -4 h-6 dpi, qd | -- | -- | 8/10** | 8.5 ± 2.1 | 77 ± 51** | 4.2 ± 4.1** |
| Ribavirin | 50 mg/kg/d, -4 h-6 dpi, bid | 3/3 | 4.4 | 9/10** | 7.0 ± 0.0 | 71 ± 46*** | 0.0 ± 5.2 |
| Ribavirin | 5 mg/kg/d, -4 h-6 dpi, bid | -- | -- | 5/9 | 7.3 ± 1.3 | 168 ± 70 | −4.3 ± 3.6 |
| Saline (study 1) | −4 h-6 dpi, bid | 3/3 | 8.7 | 2/10 | 7.6 ± 1.8 | 228 ± 75 | −6.6 ± 5.4 |
|
| |||||||
| Viramidine | 100 mg/kg/d, -4 h-6 dpi, bid | 3/3 | 6.7 | 9/10** | 13 ± 0.0 | 62 ± 28*** | 3.0 ± 2.9** |
| Saline (study 2) | 0–6 dpi, bid | 3/3 | 5.3 | 3/10 | 7.3 ± 5.7 | 252 ± 106 | −7.4 ± 6.8 |
|
| |||||||
| IFN alfacon-1 | 5 μg/kg/d, 2–8 dpi qd | 3/3 | 1.0 | 9/10* | 8.0 ± 0.0 | 100 ± 52* | 4.1 ± 3.8* |
| Ribavirin | 50 mg/kg/d, 2–8 dpi, bid | 3/3 | 4.4 | 10/10** | >21.0 ± 0.0 | 53 ± 4*** | 3.7 ± 2.2 |
| Saline (study 3) | 2–8 dpi, qd | 3/3 | 5.3 | 4/10 | 7.5 ± 0.8 | 230 ± 169 | −3.0 ± 7.5 |
| Normal controls | -- | 3/3 | 5.0 | -- | -- | -- | -- |
Data combined from several experiments
a
Number of animals surviving past 21 dpi per number of total animals challenged with virus
b
Weight change between 3 and 6 dpi, correlating with the peak weight change in placebo-treated animals
c
Mean day to death
d
Serum alanine aminotransferase (IU/L)
***
P ≤ 0.001,
**
P ≤ 0.01,
*
P ≤ 0.05 as compared with placebo